相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
Nadine Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
Katarzyna Pogoda et al.
JOURNAL OF ONCOLOGY (2020)
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
Solene De Talhouet et al.
SCIENTIFIC REPORTS (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer
Ofer Lavie et al.
GYNECOLOGIC ONCOLOGY (2019)
Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China
Mei Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines
Matthew P. Goetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
Soledad Jorge et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Germline breast cancer susceptibility gene mutations and breast cancer outcomes
Yong Alison Wang et al.
BMC CANCER (2018)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R. Copson et al.
LANCET ONCOLOGY (2018)
Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer
Allison W. Kurian et al.
JAMA ONCOLOGY (2018)
Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer
Siddhartha Yadav et al.
CLINICAL BREAST CANCER (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Barbara M. Norquist et al.
CLINICAL CANCER RESEARCH (2018)
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women
Marjanka K. Schmidt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women
Marjanka K. Schmidt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
Clinical outcomes of female breast cancer according to BRCA mutation status
Deirdre P. Cronin-Fenton et al.
CANCER EPIDEMIOLOGY (2017)
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing
Angela R. Bradbury et al.
GENETICS IN MEDICINE (2016)
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
Joanne Kotsopoulos et al.
GYNECOLOGIC ONCOLOGY (2016)
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis
Zora Baretta et al.
MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Receipt of Chemotherapy Among Medicare Patients With Cancer by Type of Supplemental Insurance
Joan L. Warren et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis
Cezary Cybulski et al.
LANCET ONCOLOGY (2015)
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
Francisco J. Candido-dos-Reis et al.
CLINICAL CANCER RESEARCH (2015)
Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong et al.
CLINICAL CANCER RESEARCH (2015)
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
M. Kriege et al.
BRITISH JOURNAL OF CANCER (2014)
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Steven A. Narod et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
S. Bayraktar et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer
Tomasz Huzarski et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study
Pamela J. Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Soley Bayraktar et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
Gad Rennert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress
Iris van Oostrom et al.
PATIENT EDUCATION AND COUNSELING (2007)
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
ME Robson et al.
BREAST CANCER RESEARCH (2004)
Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility:: Findings from p53 and BRCA1 testing programs
M Dorval et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
